By Chris Wack

 

LumiraDx Ltd. shares were up 13%, to $8.70, after the company said it has submitted the LumiraDx SARS-CoV-2 & Flu A/B Test to the U.S. Food and Drug Administration for Emergency Use Authorization.

The company said the microfluidic immunofluorescence assay can quickly verify infection for patients suspected of flu and/or Covid-19 to aid diagnosis and clinical decision making.

The LumiraDx SARS-CoV-2 & Flu A/B Test is a rapid microfluidic immunofluorescence assay intended for the simultaneous detection of SARS-CoV-2, Influenza A, and Influenza B viral antigen direct from self or clinician collected nasal swab specimens from individuals suspected of viral infection consistent with Covid-19 by their healthcare provider within the first 12 days of the onset of symptoms.

The company currently has five tests in the market globally, and an additional 10 tests scheduled for regulatory submission or clearance by the end of 2022, including tests for troponin and congestive heart failure.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

October 15, 2021 09:31 ET (13:31 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
LumiraDx (NASDAQ:LMDX)
Historical Stock Chart
From Oct 2021 to Nov 2021 Click Here for more LumiraDx Charts.
LumiraDx (NASDAQ:LMDX)
Historical Stock Chart
From Nov 2020 to Nov 2021 Click Here for more LumiraDx Charts.